SHS1 Antibody

What is SHS1 and why are antibodies against it valuable for research?

SHS1 (also known as Sep7) is one of five septins (alongside Cdc3, Cdc10, Cdc11, and Cdc12) that form the septin ring at the bud neck during vegetative growth in Saccharomyces cerevisiae. Antibodies against SHS1 are valuable research tools because they allow visualization and analysis of septin organization and function. SHS1 plays multiple roles in septin organization and cytokinesis, making it an important target for studying these fundamental cellular processes . Unlike other septins that are essential for viability, SHS1 is nonessential, allowing for functional analysis through deletion studies.

How do SHS1 antibodies differ from antibodies against other septin proteins?

SHS1 antibodies target epitopes specific to the SHS1 protein, which has distinct domains and functions compared to other septins. When designing experiments, researchers must consider that SHS1 plays separable roles in septin organization and cytokinesis, and antibodies may recognize different domains relevant to these distinct functions. An important distinction is that while other septin proteins (Cdc3, Cdc10, Cdc11, Cdc12) form the core septin complex, SHS1 appears to have supportive roles in cytokinesis and can affect septin organization differently depending on septin subunit composition .

What applications are most suitable for SHS1 antibodies?

SHS1 antibodies are particularly useful for:

• Immunofluorescence microscopy to visualize septin ring formation

• Western blotting to detect SHS1 expression levels

• Immunoprecipitation to study protein-protein interactions

• ChIP assays to investigate potential DNA interactions

When designing experiments, researchers should incorporate appropriate controls, including SHS1 deletion strains (shs1Δ), to validate antibody specificity .

What is the optimal protocol for validating SHS1 antibody specificity in yeast research?

Validating SHS1 antibody specificity requires:

• Genetic validation: Compare antibody signal between wild-type and shs1Δ strains.

• Western blot analysis:

  • Prepare lysates from both wild-type and shs1Δ strains

  • Run proteins on SDS-PAGE and transfer to membrane

  • Probe with SHS1 antibody

  • Verify presence of band at expected molecular weight (~64 kDa) in wild-type and absence in shs1Δ

• Immunofluorescence validation:

  • Fix yeast cells with formaldehyde (3-4%)

  • Permeabilize cell wall with zymolyase

  • Incubate with SHS1 antibody followed by fluorescent secondary antibody

  • Confirm bud neck localization in wild-type cells and absence of signal in shs1Δ cells

Similar to protocols used for screening antibodies against post-translational modifications, optimization of concentration and incubation times is essential for minimizing background signals .

How should researchers prepare yeast samples for optimal SHS1 antibody binding in immunofluorescence applications?

For optimal immunofluorescence results:

• Culture preparation:

  • Grow yeast to mid-log phase (OD₆₀₀ ≈ 0.6-0.8)

  • Use rich media (YPD) or selective media appropriate for your strain

• Fixation protocol:

  • Fix cells with 3.7% formaldehyde for 1 hour at room temperature

  • Wash three times with phosphate buffer (pH 7.4)

  • Digest cell walls with zymolyase (100 μg/ml) in sorbitol buffer for 20-30 minutes

• Antibody incubation:

  • Block with 1% BSA in PBS for 30 minutes

  • Incubate with primary SHS1 antibody (typically 1:100-1:500 dilution) overnight at 4°C

  • Wash 3× with PBS

  • Incubate with fluorescent secondary antibody (1:1000) for 1 hour at room temperature

  • Counterstain with DAPI to visualize nuclei

This protocol should yield clear bud neck localization of SHS1 in wild-type yeast similar to other septin visualization techniques .

How can researchers distinguish between specific and non-specific binding of SHS1 antibodies?

To distinguish between specific and non-specific binding:

• Essential controls:

  • shs1Δ strain as negative control

  • Pre-immune serum control (for polyclonal antibodies)

  • Secondary antibody-only control

• Competition assay:

  • Pre-incubate antibody with purified SHS1 protein

  • Compare signal between competed and non-competed antibody

  • Reduction in signal indicates specific binding

• Dilution series analysis:

  • Test multiple antibody dilutions (1:100, 1:500, 1:1000, 1:5000)

  • Plot signal-to-noise ratio

  • Specific binding typically shows dose-dependent response while maintaining signal localization

Applying standardized protocols similar to those used in antibody characterization initiatives helps ensure reproducible results .

What are common pitfalls when using SHS1 antibodies in co-immunoprecipitation experiments?

Common pitfalls and solutions include:

• Cross-reactivity with other septins:

  • Validate by parallel IP in shs1Δ strains

  • Confirm specificity using mass spectrometry of precipitated proteins

  • Consider using epitope-tagged SHS1 if cross-reactivity persists

• Low efficiency precipitation:

  • Optimize lysis conditions (try different detergents: NP-40, CHAPS, Triton X-100)

  • Test different antibody-to-lysate ratios

  • Extend incubation time (4-16 hours at 4°C)

• Disruption of protein complexes:

  • Use milder lysis buffers with lower detergent concentrations

  • Cross-link proteins before lysis (using DSP or formaldehyde)

  • For septin studies, consider that the complex may dissociate under harsh conditions

• High background:

  • Increase washing stringency incrementally

  • Pre-clear lysates with protein A/G beads

  • Use specific septin mutants as controls (e.g., cdc10Δ or cdc11Δ)

How can researchers overcome detection challenges in Western blots with SHS1 antibodies?

To improve Western blot detection:

• Sample preparation optimization:

  • Fresh preparation of yeast lysates using glass bead disruption

  • Include protease inhibitors to prevent degradation

  • Denature samples at lower temperatures (70°C instead of 95°C) if epitope is heat-sensitive

• Gel and transfer adjustments:

  • Use lower percentage gels (8-10%) for better separation of septins

  • Extend transfer time for high molecular weight proteins

  • Consider wet transfer instead of semi-dry for more complete transfer

• Signal enhancement strategies:

  • Increase antibody concentration incrementally

  • Extended primary antibody incubation (overnight at 4°C)

  • Use signal enhancement systems (e.g., biotin-streptavidin amplification)

  • Consider more sensitive detection methods (chemiluminescence or fluorescent secondary antibodies)

• Recommended loading controls:

  • Actin for general expression

  • Other septins like Cdc3 for comparison of septin complex components

These approaches are consistent with standard antibody characterization protocols used for validation of other research antibodies .

How should researchers design experiments to study SHS1's distinct roles in septin organization versus cytokinesis?

To differentiate between SHS1's roles:

• Genetic approach using separation-of-function mutants:

  • Utilize the shs1-100c allele (lacking C-terminal 32 amino acids) which maintains cytokinesis function but is defective in septin organization

  • Compare phenotypes between shs1Δ, shs1-100c, and wild-type strains

  • Examine double mutants (e.g., shs1-100c cdc10Δ vs. shs1-100c iqg1-1)

• Microscopy-based assay design:

  Experimental Condition	Septin Organization Analysis	Cytokinesis Analysis
  Wild-type	Measure septin ring intensity and continuity	Assess actomyosin contractile ring and septum formation
  shs1Δ	Examine Cdc3/10/11/12 localization	Measure Iqg1, Myo1, and Cyk3 localization
  shs1-100c	Examine septin organization defects	Verify normal cytokinesis
  shs1Δ cdc10Δ	Assess synthetic effects on remaining septins	Monitor exacerbated cytokinesis defects

• Protein interaction studies:

  • Immunoprecipitate wild-type SHS1 vs. SHS1-100c

  • Compare binding partners using mass spectrometry

  • Focus on interactions with Cdc12 (implicated in septin organization) vs. cytokinesis factors like Iqg1

• Recommended controls:

  • cdc10Δ (shows septin defects but maintains Myo1 localization)

  • iqg1 mutants (direct cytokinesis defects)

What considerations are important when using SHS1 antibodies to study temperature-sensitive septin mutants?

When studying temperature-sensitive mutants:

• Temperature shift protocols:

  • Grow cells at permissive temperature (25°C) to mid-log phase

  • Shift to restrictive temperature (37°C) for specific time intervals (15, 30, 60 minutes)

  • Collect samples for antibody-based assays at each time point

• Antibody validation at different temperatures:

  • Ensure antibody epitope recognition is not affected by temperature-induced conformational changes

  • Compare antibody performance at 25°C vs. 37°C in wild-type cells

  • Include non-temperature-sensitive proteins as controls

• Experimental design considerations:

  • In temperature-sensitive septin mutants (cdc3-1, cdc10-1, cdc11-1, cdc12-1), all septins disappear from the bud neck at restrictive temperature

  • Use shs1Δ as a comparison where other septins remain at the bud neck

  • Design time-course experiments to capture transitional states

• Data interpretation guidelines:

  • Distinguish between direct effects on SHS1 vs. indirect effects due to disassembly of the entire septin complex

  • Quantify relative abundance and localization patterns

  • Consider that temperature shifts may affect antibody affinity

How can researchers use SHS1 antibodies to investigate genetic interactions between SHS1 and other septin genes?

To investigate genetic interactions:

• Strategic experimental design:

  • Generate double mutants (e.g., shs1Δ cdc10Δ, shs1Δ cdc11Δ)

  • Compare growth, morphology, and cytokinesis phenotypes

  • Use antibodies against remaining septins to assess localization and complex formation

• Key assays and approaches:

  • Immunofluorescence to visualize septin localization in single vs. double mutants

  • Co-immunoprecipitation to assess complex formation

  • Western blotting to determine protein expression levels

  • Growth assays at different temperatures to reveal conditional phenotypes

• Important findings to consider:

  • Deletion of SHS1 enhances defects in cdc10Δ cells but suppresses defects in cdc11Δ cells

  • SHS1 appears to exert different effects on septin-ring assembly depending on septin subunit composition

  • The C-terminal domain of SHS1 (missing in shs1-100c) affects interactions with septin complexes but not cytokinesis functions

• Recommended controls and comparisons:

  Genotype	Expected Phenotype	Antibody Use
  Wild-type	Normal septin ring and cytokinesis	Baseline for antibody staining
  shs1Δ	Cold-sensitive growth, cytokinesis defects	Verify antibody specificity
  cdc10Δ	Growth and morphological defects	Assess septin localization without Cdc10
  shs1Δ cdc10Δ	Enhanced growth and morphological defects	Evaluate synthetic genetic interaction
  shs1Δ cdc11Δ	Suppression of cdc11Δ defects	Assess rescue phenotype

How can advanced antibody characterization techniques improve SHS1 antibody reliability?

Advanced characterization techniques include:

• Knockout cell validation:

  • Use CRISPR-Cas9 to generate SHS1 knockout lines

  • Compare antibody signals between wild-type and knockout samples

  • Apply standardized protocols across multiple applications (Western blot, immunoprecipitation, immunofluorescence)

• Epitope mapping:

  • Generate SHS1 fragments covering different domains

  • Test antibody binding to each fragment

  • Identify precise binding regions to predict potential cross-reactivity

• Mass spectrometry validation:

  • Perform immunoprecipitation followed by mass spectrometry

  • Confirm presence of SHS1 peptides in precipitated samples

  • Identify co-precipitating proteins to characterize complexes

• Recombinant antibody technologies:

  • Convert hybridoma-derived antibodies to recombinant format

  • Sequence VH and VL regions to ensure reproducibility

  • Make sequences publicly available through repositories

  • Apply standardized characterization protocols similar to those used by YCharOS

What new methodologies are being developed for studying SHS1 interactions with cytokinesis proteins?

Emerging methodologies include:

• Proximity labeling techniques:

  • Fuse SHS1 to BioID or TurboID

  • Identify proteins in close proximity to SHS1 during different cell cycle stages

  • Compare proximity profiles between wild-type SHS1 and separation-of-function mutants like SHS1-100c

• Super-resolution microscopy applications:

  • Apply PALM, STORM, or SIM to visualize septin structures below diffraction limit

  • Track dynamic changes in SHS1 localization relative to other septins and cytokinesis factors

  • Measure nanoscale distances between SHS1 and interaction partners

• Live-cell imaging with split fluorescent proteins:

  • Fuse complementary fragments to SHS1 and potential interaction partners

  • Monitor protein-protein interactions in real-time during cytokinesis

  • Correlate interaction timing with morphological changes

• Engineered antibody fragments for live-cell applications:

  • Develop SHS1-specific nanobodies or scFvs

  • Express intracellularly to visualize or perturb SHS1 function in living cells

  • Apply similar approaches to those used for VHH-derived IgG-like antibodies

How might cross-species reactive SHS1 antibodies benefit comparative studies of septin function?

Cross-species reactive antibodies would enable:

• Evolutionary conservation analysis:

  • Compare septin organization across fungal species

  • Identify conserved vs. divergent functions of SHS1 homologs

  • Correlate structural differences with functional specialization

• Model system expansion:

  • Apply validated antibodies across multiple yeast species (S. cerevisiae, C. albicans, S. pombe)

  • Compare septin dynamics in different morphological contexts (budding vs. fission)

  • Develop experimental platforms for comparative septin biology

• Epitope selection strategies:

  • Target highly conserved regions for cross-species reactivity

  • Use sequence alignment to identify suitable epitopes

  • Validate using recombinant proteins from multiple species

• Validation requirements:

  • Test specificity in each target species

  • Include species-specific knockout controls

  • Characterize potential cross-reactivity with species-specific septin paralogs

This approach would benefit from standardized antibody characterization methods similar to those developed for human protein antibodies by initiatives like YCharOS .

How should researchers quantitatively analyze immunofluorescence data from SHS1 antibody experiments?

Quantitative analysis guidelines:

• Standardized image acquisition parameters:

  • Maintain consistent exposure times and microscope settings

  • Image multiple fields (>10) per condition

  • Include wild-type and shs1Δ controls in each experiment

• Recommended quantification metrics:

  Metric	Description	Application
  Signal intensity	Mean fluorescence at bud neck	Protein abundance assessment
  Ring continuity	Coefficient of variation around ring	Structural integrity analysis
  Ring diameter	Measured at widest point	Structural organization assessment
  Co-localization	Pearson's correlation with other proteins	Interaction analysis

• Statistical analysis approach:

  • Compare minimum of 30 cells per condition

  • Apply appropriate statistical tests (t-test or ANOVA)

  • Report means, standard deviations, and p-values

  • Include effect sizes for meaningful comparisons

• Software tools and workflows:

  • ImageJ/Fiji with custom macros for automated analysis

  • CellProfiler for high-throughput phenotyping

  • R or Python for statistical analysis and visualization

These approaches align with standard practices in antibody validation studies .

What criteria should be used to interpret SHS1 antibody results in the context of septin organization studies?

Interpretation criteria:

• Localization pattern assessment:

  • Normal: Continuous ring at bud neck

  • Abnormal patterns:

    • Discontinuous/fragmented rings

    • Mislocalized puncta

    • Diffuse cytoplasmic signal

    • Ectopic structures

• Temporal dynamics evaluation:

  • Cell-cycle dependent changes in localization

  • Stability during environmental stresses

  • Reorganization timing during cytokinesis

• Context-dependent interpretation guidelines:

  • In wild-type cells: Clear bud neck localization expected

  • In septin mutants (cdc10Δ, cdc11Δ): Consider altered complex formation

  • In cytokinesis mutants: Evaluate septin ring stability independently from cytokinesis defects

• Comparison matrix for result interpretation:

  Observation	Interpretation	Additional Tests
  SHS1 signal absent in cdc10Δ	SHS1 requires Cdc10 for localization	Test shs1-100c localization
  SHS1 present in cdc11Δ	SHS1 can incorporate independent of Cdc11	Assess functionality through cytokinesis markers
  Normal septin ring but abnormal Myo1/Iqg1/Cyk3	Separation of septin organization and cytokinesis functions	Test synthetic interactions with cytokinesis mutants

These criteria are informed by the separation of function observed between septin organization and cytokinesis roles of SHS1 .

What validation standards should researchers apply when selecting commercial SHS1 antibodies?

Validation standards to consider:

• Essential documentation:

  • Evidence of testing in knockout/deletion backgrounds

  • Application-specific validation data (WB, IF, IP)

  • Lot-specific quality control information

  • Detailed epitope information when available

• Minimum validation requirements:

  • Western blot showing single band at expected molecular weight

  • Immunofluorescence showing expected bud neck localization

  • Evidence of specificity in shs1Δ background

  • Batch-to-batch consistency data

• Advanced validation considerations:

  • Mass spectrometry verification of immunoprecipitated protein

  • Independent validation across multiple cell types/species

  • Comparison with orthogonal detection methods

  • Performance in relevant genetic backgrounds (cdc10Δ, cdc11Δ)

These standards align with guidelines from antibody characterization initiatives like YCharOS and general antibody validation principles .

How can researchers contribute to improving SHS1 antibody characterization in the scientific community?

Researchers can contribute by:

• Data sharing practices:

  • Publish detailed antibody validation data as supplementary information

  • Deposit validation protocols in repositories (protocols.io)

  • Report both positive and negative results with specific antibody clones

  • Include Research Resource Identifiers (RRIDs) in publications

• Community-based validation:

  • Participate in collaborative characterization initiatives

  • Share validation data through antibody validation databases

  • Contribute to open-science platforms focused on reagent validation

• Standardized reporting recommendations:

  • Document exact experimental conditions

  • Report antibody clone, lot number, and source

  • Describe all validation steps performed

  • Include appropriate positive and negative controls

• Collaborative improvement strategies:

  • Develop shared resources for SHS1 knockout lines

  • Establish consortia for septin antibody characterization

  • Generate and share recombinant SHS1 for antibody validation

These approaches would align with broader antibody reproducibility initiatives described in recent literature .